Journal article
Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy
Nuclear Medicine Communications, Vol.28(4), pp.261-266
2007
Abstract
AIM: To determine if dimercaptosuccinic acid (DMSA), an agent originally developed as a safe non-toxic antidote for heavy metal poisoning, would be useful as a kidney radiation dose reduction agent in patients undergoing radiopeptide therapy for cancer. METHODS: Thirty-six adult male Wistar rats were injected via the penile vein with 10 MBq of Lu-DOTA-tyr(3)-octreotate. At 30 min after the radiopeptide injection, 18 of the animals (intervention group) were injected with 0.15 mg·g of DMSA (i.p.). Samples were collected for gamma counting at 24 (n=12), 48 (n=12) and 72 h (n=12) after administration of the radiopeptide. At each time point, the percentage injected dose per gram of tissue in each sample of the six control animals was compared with that of the six animals from the DMSA injection regimen. RESULTS: The i.p. injection of 0.15 mg·g of DMSA 30 min following the administration of the Lu-DOTATATE reduced the mean (95% CI) kidney retention of radiopeptide by 15.6% (2.6-24.6) at 72 h while not significantly affecting uptake in other organs. Statistical testing of the difference between the two groups of animals (DMSA versus controls) at 72 h post-administration of the radiopeptide indicated only a 3% chance that the magnitude of the reduction in kidney radiopeptide retention observed would be expected due to natural variation (i.e., if there was no difference between the groups). CONCLUSION: This study has indicated that DMSA has the potential to selectively reduce radiopeptide kidney retention. Further work is necessary to determine the most effective dose of DMSA and the most effective timing regimen, and to examine the clinical efficacy of several other chelating agents.
Details
- Title
- Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy
- Authors/Creators
- R.E. Moorin (Author/Creator)D.P. Meyrick (Author/Creator)A. Rose (Author/Creator)
- Publication Details
- Nuclear Medicine Communications, Vol.28(4), pp.261-266
- Publisher
- Lippincott Williams and Wilkins
- Identifiers
- 991005543373807891
- Copyright
- © 2007 Lippincott Williams & Wilkins, Inc.
- Murdoch Affiliation
- School of Engineering Science
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
43 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.195 Neuroendocrine & Intestinal Disorders
- 1.195.565 Neuroendocrine Tumors
- Web Of Science research areas
- Radiology, Nuclear Medicine & Medical Imaging
- ESI research areas
- Clinical Medicine